Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Results of Operations and Financial Condition

Amarin Corporation plc (NASDAQ:AMRN) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02.

Results of Operations and Financial
Condition.

On February28, 2017, Amarin Corporation plc issued a press
release announcing its financial results for the three and twelve
months ended December31, 2016 (the Press Release). A copy of the
Press Release is furnished herewith as Exhibit 99.1.

The information in this report furnished to Item 2.02 shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section. It may only be
incorporated by reference in another filing under the Exchange
Act or the Securities Act of 1933, as amended, if such subsequent
filing specifically references the information furnished to Item
2.02 of this report.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1 Press Release, dated February28, 2017

* * *


About Amarin Corporation plc (NASDAQ:AMRN)

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Amarin Corporation plc (NASDAQ:AMRN) Recent Trading Information

Amarin Corporation plc (NASDAQ:AMRN) closed its last trading session up +0.11 at 3.43 with 1,739,786 shares trading hands.

An ad to help with our costs